Insulet Corporation (PODD) Securities Class Action Lawsuit Update

• Company: Insulet Corporation (NASDAQ: PODD)
• Lead Plaintiff Deadline: August 31, 2026
• Class Period: February 21, 2025 - May 26, 2026
• Stock Drop: March 13, 2026 - PODD fell $16.23 (6.88%) to $219.84; May 27, 2026 - PODD fell $7.79 (5.07%) to $146.01
• Lawsuit Type: Securities Class Action

Introduction

On July 2, 2026, a securities class action was filed in the United States District Court for the District of Massachusetts against Insulet Corporation and six of its current and former senior executives. The complaint covers investors who purchased or otherwise acquired Insulet securities between February 21, 2025 and May 26, 2026. Named alongside the company are Ashley A. McEvoy, its President and Chief Executive Officer; James R. Hollingshead, her predecessor; Flavia H. Pease and Ana M. Chadwick, its current and former Chief Financial Officers; Eric Benjamin, its Chief Operating Officer; and Trang Ly, its Chief Medical Officer.

Insulet built its reputation on the Omnipod, a tubeless, wearable insulin pod that delivers medicine to people with diabetes. Throughout the class period, according to the complaint, the company told investors it could manufacture these sophisticated electromechanical devices at consumer scale while holding to medical-grade quality and safety. Executives touted a decade of investment, advanced automation, and a robust global supply chain. According to the complaint, investors purchased Insulet securities at allegedly inflated prices during the class period.

Then Insulet disclosed manufacturing issues affecting certain Omnipod lots. The complaint alleges that beneath the assurances of quality lay defective manufacturing controls, a hidden risk that Insulet's products could violate safety regulations or pose a risk of injury to patients who used the products. When the company disclosed a voluntary Medical Device Correction in March 2026, and then a far larger one in May 2026 affecting roughly seven million pods, the market reacted sharply and the shares fell across two separate sessions.

Backdrop and Business Context

Insulet Corporation states that it was founded in 2000 by a father determined to help his son, and the company is now headquartered in Acton, Massachusetts. That founding vision, a tubeless, disposable, wearable pod, became the defining strategic thread of the company. Insulet went public on the Nasdaq Global Market on May 15, 2007, pricing its offering at $15.00 per share and selling 7,700,000 shares to raise approximately $115.5 million before the underwriters' option.

Insulet develops, manufactures, and sells the Omnipod family of insulin management systems, trading on NASDAQ under the ticker PODD. Its revenue rests almost entirely on a recurring, annuity-style model: patients replace the disposable pods every few days, generating continuous consumable sales, largely distributed through the pharmacy channel on a pay-as-you-go basis. The flagship Omnipod 5 is an automated insulin delivery system that integrates with a continuous glucose monitor. The company reported full-year 2025 revenue of approximately $2.7 billion and employs roughly 5,400 people globally, with products available in about 25 countries and more than 600,000 customers. In the diabetes device landscape, Insulet competes with Medtronic and Tandem Diabetes Care, while Dexcom operates in the adjacent glucose-monitoring space.

Manufacturing sits at the heart of the business. Insulet produces its pods through highly automated lines in Acton, Massachusetts, a plant in Malaysia opened in June 2024, and a contract manufacturer in China. According to the complaint, the company's manufacturing controls and procedures were defective in ways that created a foreseeable risk that its products would be found to violate safety regulations or pose a risk of injury, contradicting its repeated public assurances of medical-grade quality.

Promises Made vs. Reality

The class period opened on February 21, 2025, when then-CEO James Hollingshead told investors on an earnings call that Insulet had put years into building the Omnipod 5 "at scale with quality, high yield, safety and very well protected IP." That same day, the company's FY 2024 Form 10-K described a highly automated manufacturing operation and detailed its "Quality Assurance" efforts, representing that its Quality team audited outside vendors and "inspects and tests our products at various steps in the manufacturing cycle to facilitate compliance with our specifications."

The theme of quality-at-scale ran through subsequent quarters. In May 2025, then-CFO Ana Chadwick pointed to "significant investments" the company had made and would continue to make "in manufacturing and advanced automation." By the August 2025 earnings call, new CEO Ashley McEvoy reinforced the message, noting that Insulet had invested more than $1 billion in manufacturing capabilities over the prior decade, "pioneered advanced automation in our plants and built a robust and secure global supply chain to deliver tens of millions of complex electromechanical devices per year at medical standards." On the same call, Eric Benjamin tied strong sales directly to product safety, stating flatly that "Omnipod 5 is safe, effective, understood to be really easy to use."

The safety narrative intensified into the fall. At the Wells Fargo Healthcare Conference in September 2025, McEvoy described Insulet's competitive moats as including "clinical evidence around showing performance and both efficacy as well as safety," and characterized the technology as "efficacious and safer." In November 2025, she assured investors that the Acton and Malaysia facilities were "ramping ahead of plan, delivering strong customer service and improved margins." The FY 2025 Form 10-K, filed February 18, 2026, repeated verbatim the same quality-assurance representations as the prior annual report. On the accompanying earnings call, McEvoy emphasized the Omnipod's "strong proven clinical performance, both efficacy and safety," and said the company produces "tens of millions of Pods with high-quality medical-grade quality at consumer electronic scale."

Even after the first Medical Device Correction surfaced, the reassurances continued. In the March 2026 announcement, Insulet stated that "all other Omnipod 5 Pods and Omnipod products remain safe to use" and framed the issue as localized to "specific lots." The next day, Chief Medical Officer Trang Ly told a diabetes technology conference that the problem "affected only a very small number of pods," citing 1.5% of the prior year's production, and assured that "the pods that are not recalled are very safe to use." On the May 2026 earnings call, McEvoy reiterated that "patient safety is always our #1 priority," described "targeted corrective actions," and reported that no additional adverse events had been reported since an April 10 update.

As alleged in the complaint, these statements were materially false and misleading because Insulet's manufacturing controls and procedures were defective, the manufacturing issue affected a far greater number of pods than the company claimed, and this created a foreseeable heightened risk that Insulet products would be found to violate safety regulations or pose a risk of injury.

Timeline of Alleged Misconduct and Disclosures

Class Period: February 21, 2025 -- May 26, 2026, inclusive.

February 21, 2025: Class period begins. Insulet reports Q4 and full-year 2024 results; CEO Hollingshead assures investors the Omnipod 5 was built "at scale with quality... [and] safety." Company files FY 2024 Form 10-K with quality-assurance representations.

May 8-9, 2025: Q1 2025 earnings call and Form 10-Q; CFO Chadwick touts "significant investments... in manufacturing and advanced automation."

August 7, 2025: Q2 2025 Form 10-Q and earnings call; CEO McEvoy cites a "robust and secure global supply chain" delivering devices "at medical standards"; Benjamin states "Omnipod 5 is safe."

September 4, 2025: Wells Fargo Healthcare Conference; McEvoy touts safety as a "competitive moat."

November 6, 2025: Q3 2025 Form 10-Q and earnings call; McEvoy says Acton and Malaysia facilities are "delivering strong customer service."

February 18, 2026: FY 2025 Form 10-K filed with repeated quality-assurance representations; FY 2025 earnings call touts "strong proven clinical performance, both efficacy and safety."

March 12, 2026 Alleged Corrective Disclosure: Insulet initiates a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods, citing a manufacturing issue where pods "may have a small tear in the internal tubing that delivers insulin."

March 13, 2026: Stock falls $16.23 per share (6.88%) to close at $219.84. CMO Ly tells a diabetes conference the issue was limited to 1.5% of pods.

April 29, 2026: The FDA posted that Insulet had reported 476 serious injuries associated with the correction; Insulet responded that the FDA was referring to 476 Medical Device Reports, not 29 confirmed Serious Adverse Events, and the complaint notes that the FDA website no longer referenced the 476 serious-injuries figure as of April 30, 2026.

May 6, 2026: Q1 2026 earnings call; McEvoy reiterates safety and "targeted corrective actions."

May 26, 2026 Alleged Corrective Disclosure: Insulet initiates a second voluntary Medical Device Correction for Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System (Eros) Pods, affecting approximately 7 million pods, about 8.5% of 2025 global production, distributed in the U.S. and international markets. Class period ends.

May 27, 2026: Stock falls $7.79 per share (5.07%) to close at $146.01. Analysts at BTIG and Goldman Sachs lower price targets.

Investor Harm and Market Reaction

The first blow came on March 13, 2026. After Insulet disclosed the initial voluntary Medical Device Correction for specific lots of Omnipod 5 Pods, its stock price fell $16.23 per share, a decline of 6.88%, to close at $219.84. The company described the affected pods as a limited subset and stated that all other products remained safe to use.

Those assurances proved short-lived. On May 26, 2026, Insulet disclosed a second and far broader Medical Device Correction, this one spanning the Omnipod 5, Omnipod Dash, and legacy Omnipod Eros lines, affecting approximately 7 million pods, or roughly 8.5% of 2025 global production, across both the U.S. and international markets. The company also revealed that both corrections stemmed from cannula tears associated with cannula handling at the Acton, Massachusetts facility. On this news, the stock fell $7.79 per share, a decline of 5.07%, to close at $146.01 on May 27, 2026.

The market reaction extended beyond the price drops themselves. Analysts lowered their targets on the news. BTIG cut its price target roughly 9.6%, from $260 to $235, citing "continued negative investor sentiment" and "some risk of reputation damage or increased regulatory scrutiny from this second" correction. Goldman Sachs wrote that it was "not so sure that referencing back to the March MDC sufficiently captures the magnitude of the quality issues" and lowered its estimates. PODD's closing price declined from $219.84 on March 13, 2026 to $146.01 on May 27, 2026.

Litigation & Procedural Posture

The complaint asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against all defendants, and under Section 20(a) against the individual defendants as controlling persons.

The named defendants are Insulet Corporation and individual defendants Ashley A. McEvoy (President and Chief Executive Officer from April 28, 2025), James R. Hollingshead (President and Chief Executive Officer through April 28, 2025), Flavia H. Pease (Chief Financial Officer from September 30, 2025), Ana M. Chadwick (Chief Financial Officer through September 30, 2025), Eric Benjamin (Chief Operating Officer from August 25, 2025; Chief Product and Customer Experience Officer through August 25, 2025), and Trang Ly (Chief Medical Officer).

Scienter allegations center on the individual defendants' senior positions, their access to material non-public information about Insulet's internal affairs, and their repeated public statements concerning product safety and manufacturing quality. The complaint alleges that defendants had both the motive and opportunity to commit fraud, pointing to insider stock sales during the class period. According to the complaint, the individual defendants collectively sold 21,180 shares for over $5.9 million, with Benjamin selling 12,594 shares for approximately $3.7 million, Hollingshead selling 6,821 shares for approximately $1.8 million, and Chadwick selling 1,765 shares for approximately $441,691. No confidential witnesses are cited.

Procedurally, the case is at the pleading stage, having been filed on July 2, 2026 as a putative class action under Federal Rule of Civil Procedure 23. Plaintiff seeks certification of a class of all persons and entities that purchased or acquired Insulet securities during the class period. The lead plaintiff deadline is August 31, 2026.

SEC Filings & Risk Factors

The complaint's theory of liability rests substantially on Insulet's periodic SEC filings and their alleged gap between disclosed quality assurances and the omitted reality of defective manufacturing controls. The pattern, as alleged, is one of repeated representations of medical-grade quality alongside a failure to disclose that the company's manufacturing controls and procedures were deficient.

The FY 2024 Form 10-K, filed February 21, 2025, described Insulet's highly automated manufacturing at its Acton facility and, beginning June 2024, at its new Malaysia plant, along with a contract manufacturer in China. The filing represented that outside vendors "produce the components to our specifications, and they are audited periodically by our Quality team," and that "Our Quality team also inspects and tests our products at various steps in the manufacturing cycle to facilitate compliance with our specifications." According to the complaint, these representations were materially misleading given the defective controls that allegedly existed.

The FY 2025 Form 10-K, filed February 18, 2026, repeated substantially identical quality-assurance language. The complaint also cites the quarterly reports on Form 10-Q filed May 9, August 7, and November 6, 2025, each of which stated that the company "anticipate[d] gross margin to increase compared with 2024 primarily due to improved manufacturing efficiencies," a forward-looking assurance the complaint alleges was inconsistent with the true state of manufacturing controls.

The complaint identifies the March 12 and May 26 Medical Device Corrections as the alleged corrective disclosures. The March 12, 2026 Medical Device Correction revealed that certain Omnipod 5 pods "may have a small tear in the internal tubing that delivers insulin," allowing insulin to leak inside the pod. The May 26, 2026 Medical Device Correction, and the related Regulation FD disclosure, revealed that both corrections were tied to cannula handling at the Acton facility, that approximately 7 million pods were affected, and that the products at issue had been manufactured before the enhanced quality controls implemented after the first correction were put in place. The synthesis of these disclosures, as alleged in the complaint, is that the alleged manufacturing risk had become concrete through the March and May Medical Device Corrections, while defendants allegedly continued to assure investors of medical-grade quality and localized, contained issues, an omission material to any reasonable investor evaluating the durability of Insulet's core pod business.

How to Check Eligibility in the Insulet Corporation (PODD) Class Action

Confirm you purchased PODD shares during the February 21, 2025 to May 26, 2026 class period

• Review the allegations and eligibility requirements in the pending securities class action
• Gather trade confirmations and brokerage records documenting purchases or losses
• Consult counsel regarding the lead plaintiff deadline, eligibility, and any potential rights in the litigation

Disclaimer: Attorney Advertising. This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.